MX2022010014A - Composicion farmaceutica liquida que comprende ensifentrina y glicopirrolato. - Google Patents
Composicion farmaceutica liquida que comprende ensifentrina y glicopirrolato.Info
- Publication number
- MX2022010014A MX2022010014A MX2022010014A MX2022010014A MX2022010014A MX 2022010014 A MX2022010014 A MX 2022010014A MX 2022010014 A MX2022010014 A MX 2022010014A MX 2022010014 A MX2022010014 A MX 2022010014A MX 2022010014 A MX2022010014 A MX 2022010014A
- Authority
- MX
- Mexico
- Prior art keywords
- glycopyrrolate
- pharmaceutical composition
- liquid pharmaceutical
- ensiphenthrine
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002786.8A GB202002786D0 (en) | 2020-02-27 | 2020-02-27 | Liquid pharmaceutical composition |
| PCT/GB2021/050496 WO2021171034A1 (en) | 2020-02-27 | 2021-02-26 | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010014A true MX2022010014A (es) | 2022-10-18 |
Family
ID=70278709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010014A MX2022010014A (es) | 2020-02-27 | 2021-02-26 | Composicion farmaceutica liquida que comprende ensifentrina y glicopirrolato. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20230112220A1 (OSRAM) |
| EP (2) | EP4306129A3 (OSRAM) |
| JP (2) | JP7781762B2 (OSRAM) |
| KR (1) | KR20220149669A (OSRAM) |
| CN (1) | CN115279343A (OSRAM) |
| AU (1) | AU2021227456A1 (OSRAM) |
| BR (1) | BR112022016015A2 (OSRAM) |
| CA (1) | CA3166952A1 (OSRAM) |
| DK (1) | DK4110292T3 (OSRAM) |
| ES (1) | ES2970571T3 (OSRAM) |
| FI (1) | FI4110292T3 (OSRAM) |
| GB (1) | GB202002786D0 (OSRAM) |
| HR (1) | HRP20240288T1 (OSRAM) |
| HU (1) | HUE065531T2 (OSRAM) |
| IL (1) | IL295442A (OSRAM) |
| LT (1) | LT4110292T (OSRAM) |
| MX (1) | MX2022010014A (OSRAM) |
| PH (1) | PH12022552278A1 (OSRAM) |
| PL (1) | PL4110292T3 (OSRAM) |
| PT (1) | PT4110292T (OSRAM) |
| RS (1) | RS65330B1 (OSRAM) |
| SI (1) | SI4110292T1 (OSRAM) |
| SM (1) | SMT202400076T1 (OSRAM) |
| WO (1) | WO2021171034A1 (OSRAM) |
| ZA (1) | ZA202208763B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3231444T3 (pl) | 2014-05-12 | 2020-05-18 | Verona Pharma Plc | Nowe leczenie |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| EP4609864A4 (en) * | 2022-10-28 | 2026-02-18 | Jiangsu Hengrui Pharmaceuticals Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING AN ISOQUINOLINONE COMPOUND AND RELATED PREPARATION PROCESS |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| CN121620356A (zh) | 2023-06-26 | 2026-03-06 | 维罗纳制药公司 | 包含恩塞芬汀的颗粒组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2368413C (en) | 1999-03-31 | 2008-07-29 | Verona Pharma Plc | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| NZ587561A (en) * | 2008-02-26 | 2012-10-26 | Elevation Pharmaceuticals Inc | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist) |
| SI2968313T1 (en) | 2013-03-15 | 2018-05-31 | Verona Pharma Plc | Combination of medicines |
| PT3332767T (pt) * | 2014-09-15 | 2019-06-27 | Verona Pharma Plc | Formulação por inalação líquida compreendendo rpl554 |
-
2020
- 2020-02-27 GB GBGB2002786.8A patent/GB202002786D0/en not_active Ceased
-
2021
- 2021-02-26 DK DK21709782.3T patent/DK4110292T3/da active
- 2021-02-26 PH PH1/2022/552278A patent/PH12022552278A1/en unknown
- 2021-02-26 SM SM20240076T patent/SMT202400076T1/it unknown
- 2021-02-26 MX MX2022010014A patent/MX2022010014A/es unknown
- 2021-02-26 EP EP23213674.7A patent/EP4306129A3/en active Pending
- 2021-02-26 BR BR112022016015A patent/BR112022016015A2/pt unknown
- 2021-02-26 FI FIEP21709782.3T patent/FI4110292T3/fi active
- 2021-02-26 JP JP2022551825A patent/JP7781762B2/ja active Active
- 2021-02-26 IL IL295442A patent/IL295442A/en unknown
- 2021-02-26 CA CA3166952A patent/CA3166952A1/en active Pending
- 2021-02-26 HU HUE21709782A patent/HUE065531T2/hu unknown
- 2021-02-26 PL PL21709782.3T patent/PL4110292T3/pl unknown
- 2021-02-26 EP EP21709782.3A patent/EP4110292B1/en active Active
- 2021-02-26 ES ES21709782T patent/ES2970571T3/es active Active
- 2021-02-26 KR KR1020227029927A patent/KR20220149669A/ko active Pending
- 2021-02-26 HR HRP20240288TT patent/HRP20240288T1/hr unknown
- 2021-02-26 LT LTEPPCT/GB2021/050496T patent/LT4110292T/lt unknown
- 2021-02-26 AU AU2021227456A patent/AU2021227456A1/en active Pending
- 2021-02-26 SI SI202130101T patent/SI4110292T1/sl unknown
- 2021-02-26 PT PT217097823T patent/PT4110292T/pt unknown
- 2021-02-26 US US17/904,816 patent/US20230112220A1/en active Pending
- 2021-02-26 RS RS20240350A patent/RS65330B1/sr unknown
- 2021-02-26 CN CN202180016396.7A patent/CN115279343A/zh active Pending
- 2021-02-26 WO PCT/GB2021/050496 patent/WO2021171034A1/en not_active Ceased
-
2022
- 2022-08-04 ZA ZA2022/08763A patent/ZA202208763B/en unknown
-
2025
- 2025-11-26 JP JP2025203938A patent/JP2026035711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2970571T3 (es) | 2024-05-29 |
| JP2026035711A (ja) | 2026-03-04 |
| CN115279343A (zh) | 2022-11-01 |
| SI4110292T1 (sl) | 2024-03-29 |
| FI4110292T3 (fi) | 2024-03-01 |
| LT4110292T (lt) | 2024-02-12 |
| GB202002786D0 (en) | 2020-04-15 |
| KR20220149669A (ko) | 2022-11-08 |
| EP4110292A1 (en) | 2023-01-04 |
| JP7781762B2 (ja) | 2025-12-08 |
| SMT202400076T1 (it) | 2024-03-13 |
| EP4110292B1 (en) | 2024-01-10 |
| IL295442A (en) | 2022-10-01 |
| AU2021227456A1 (en) | 2022-09-08 |
| EP4306129A3 (en) | 2024-04-17 |
| DK4110292T3 (da) | 2024-02-19 |
| BR112022016015A2 (pt) | 2022-10-11 |
| RS65330B1 (sr) | 2024-04-30 |
| PH12022552278A1 (en) | 2024-03-04 |
| HUE065531T2 (hu) | 2024-05-28 |
| JP2023516630A (ja) | 2023-04-20 |
| WO2021171034A1 (en) | 2021-09-02 |
| PL4110292T3 (pl) | 2024-05-20 |
| US20230112220A1 (en) | 2023-04-13 |
| CA3166952A1 (en) | 2021-09-02 |
| ZA202208763B (en) | 2024-01-31 |
| HRP20240288T1 (hr) | 2024-05-24 |
| PT4110292T (pt) | 2024-01-31 |
| EP4306129A2 (en) | 2024-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202208763B (en) | Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate | |
| Bourgonje et al. | N-acetylcysteine and hydrogen sulfide in coronavirus disease 2019 | |
| Garibaldi et al. | Isolation and properties of ferrichrome A | |
| EA201200490A1 (ru) | Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения | |
| Nishiwaki et al. | Two significant aspects of microcystin-LR: specific binding and liver specificity | |
| TNSN08445A1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| MX2009004475A (es) | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. | |
| US20020022655A1 (en) | Leukemic cell growth inhibiting method | |
| Herget et al. | Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats | |
| FR3041639B1 (fr) | NOUVEAUX DERIVES D'IMIDAZO[4,5-b]PYRIDINE, PROCEDE POUR LES PREPARER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
| MX2024014435A (es) | Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington | |
| ATE391730T1 (de) | Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung | |
| Hwang et al. | Optimization of peptide-based inhibitors targeting the HtrA serine protease in Chlamydia: Design, synthesis and biological evaluation of pyridone-based and N-Capping group-modified analogues | |
| Liu et al. | Sodium sulfite-triggered hepatocyte ferroptosis via mtROS/lysosomal membrane permeabilization-mediated lysosome iron efflux | |
| CN109806392A (zh) | 稳定的抗cd43单克隆抗体的液体制剂 | |
| WO2011111070A2 (en) | Novel injectable combination | |
| Zhang et al. | Ascorbyl palmitate ameliorates inflammatory diseases by inhibition of NLRP3 inflammasome | |
| CN102526036A (zh) | 一种含有丁苯酞和依达拉奉的复方注射液及制备方法 | |
| Toussaint et al. | Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction? | |
| Jackson et al. | Adenosine biosynthesis in the collecting duct | |
| CN111759880A (zh) | 淫羊藿药材提取物及其在预防或治疗冠状病毒中的应用 | |
| RU2006224C1 (ru) | Мембраностабилизирующее и антиоксидантное лекарственное средство "рикавит" | |
| EP1988972A2 (de) | Proteasom- oder ups-inhibitor zur behandlung von infektionen mit influenza-viren | |
| BRPI0115076B8 (pt) | preparação farmacêutica, sua aplicação farmacêutica, bem como processo para preparação da mesma | |
| US20210171607A1 (en) | Method for producing hypo-metallated redox-active metallothionein protein and pharmaceutical composition containing the same |